PETS

PetMed Express Inc. (PETS) - Q3 2026 10-Q Summary

Business Context and Reporting Period

PetMed Express, Inc. is a direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, and supplies. This report covers the quarterly period ended December 31, 2025 (the third quarter of fiscal year 2026). The Company operates under a March 31 fiscal year-end. The filing includes a restatement of prior period financials due to material errors in accounting for vendor reimbursements and advertising costs.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 21.7% quarter-over-quarter and 22.7% year-to-date, driven by a decline in prescription medication sales and higher consumer promotional usage. Reorder sales dropped 23.0% and new order sales dropped 15.5% in the quarter.
• Profitability Deterioration: Gross margin compressed significantly due to a $2.1 million inventory write-down related to unsold inventory from a failed wholesale transaction. This write-down, combined with lower sales volume, reduced gross profit by 41.4% in the quarter.
• Operating Expenses: General and administrative expenses increased 13.1% in the quarter and 50.3% year-to-date. The YTD increase was primarily driven by $3.2 million in professional fees related to a whistleblower investigation and executive departures.
• Impairments: While no new goodwill impairment occurred in Q3, the Company recorded a $26.7 million goodwill impairment and a $0.6 million intangible asset impairment in the prior quarter (ended June 30, 2025), which contributed to the significant YTD net loss.
• Liquidity: Cash and cash equivalents decreased by $27.8 million over the nine-month period, resulting in a net cash burn of $23.7 million from operating activities.

Guidance, Outlook, and Risks

• Restatement: The Company restated prior period financials to correct errors in accounting for vendor-funded programs, reclassifying certain reimbursements from revenue to cost of sales and adjusting advertising expenses.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2025, due to unremediated material weaknesses in internal control over financial reporting. Remediation efforts are ongoing.
• Acquisition Proposals: In December 2025, the Company received unsolicited, non-binding acquisition proposals ranging from $4.00 to $4.25 per share. The Board is reviewing these proposals.
• Legal Proceedings: The Company is defending a class action lawsuit regarding alleged "illusory discounts" on product pricing. No liability has been accrued as the outcome is uncertain.
• Outlook: Management expects macroeconomic factors, including inflation and consumer cost optimization, to continue impacting revenue growth rates for the remainder of fiscal 2026. The Company has suspended dividends indefinitely to preserve cash.

Investor Verification Checklist

• Inventory Valuation: Verify the recoverability of the remaining $2.3 million in inventory related to the failed wholesale transaction and the sufficiency of the $2.1 million write-down.
• Restatement Impact: Review the full details of the accounting error correction regarding vendor reimbursements to understand the true historical cost structure and gross margins.
• Investigation Costs: Confirm that the $4.5 million in costs related to the whistleblower investigation (legal fees and severance) represents the total expected liability.
• Internal Control Remediation: Monitor the progress of remediation plans for material weaknesses in internal controls, specifically regarding revenue recognition and vendor arrangements.
• Acquisition Status: Track the Board's decision-making process regarding the unsolicited acquisition proposals and any potential impact on share price or corporate strategy.